KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”
31.3.2023 17:09:00 EEST | Business Wire | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005155/en/
(Figure 1) Recycling-oriented Biomanufacturing Technology (Graphic: Business Wire)
This project will contribute to the realization of carbon recycling in the "Green Growth Strategy Through Achieving Carbon Neutrality in 2050" formulated by the Ministry of Economy, Trade and Industry with related ministries and agencies on December 25, 2020 (revised on June 18, 2021). The goal of the project is to realize recycling-oriented biomanufacturing technology that does not depend on fossil resources by developing microorganisms that produce biodegradable polymers from CO2 and developing production process technology, combining the knowledge and technology that the four companies have cultivated over the years.
During the project period (FY2023 to FY2030), the following three themes will be addressed.
- Establishment of a gas fermentation biofoundry*2 using CO2 as a raw material (Bacchus and Shimadzu)
- Development and improvement of biopolymer-producing microorganisms (Kaneka)
- Development and demonstration of production technology using microorganisms capable of producing substances from CO2 (Kaneka, JGC HD, Shimadzu)
[ Kaneka ] https://www.kaneka.co.jp/en/
Kaneka is the first company in the world to successfully commercialize KANEKA Biodegradable Polymer Green PlanetTM ("Green Planet"), which is produced by microorganisms from vegetable oil and other raw materials. In this project, based on the synthetic microbiology and polymer production, processing technologies it has cultivated to date, Kaneka will develop new microorganisms that produce Green Planet directly from CO2, and will also launch a semi-commercial plant to conduct production demonstration for Green Planet industrialization. In addition, we will lead this project as the managing company.
[ Bacchus ] https://www.b2i.co.jp/
Bacchus is a data-driven biofoundry company. Bacchus aims to drastically shorten the breeding time of smart cells*3 by upgrading the breeding platform consolidating its proprietary technologies. By utilizing its own digital technology, Bacchus will design cells optimized for gas fermentation and create a variety of species. In addition, they will introduce and utilize data from a high-throughput evaluation system jointly developed with Shimadzu, and aim to build an "Integrated Biofoundry*4" that will provide one-stop service from microbial breeding to process development with JGC HD.
[ JGC HD ] https://www.jgc.com/en/
JGC HD has a profound knowledge of the safe gas handling of gases including hydrogen gas and process scale-up cultivated through its EPC (Engineering, Procurement, and Construction) business in the oil and gas fields, as well as in optimized culture tank design technology in the life science field. In this project, JGC HD will develop and scale-up a safe handling system for mixed gases containing CO2, H2, and O2 and a highly efficient gas fermentation process in addition to establishing an “Integrated Biofoundry” with Bacchus which will provide a one-stop service from microbial breeding to process development.
[ Shimadzu ] https://www.shimadzu.com/
Shimadzu, with the aim of solving social issues, has accumulated a variety of know-how by providing analytical measurement and robotics technologies to a wide range of fields and data analysis technologies using AI-based systems. In this project, Shimadzu will work on the development of high-speed productivity evaluation technology, which is indispensable for the construction of a biofoundry. Shimadzu will also develop an evaluation system to measure gas fermentation in the semi-commercial plant which is to be constructed as part of the project and support safe and highly efficient fermentation.
*1. A project to support companies and others working on management issues toward Japan's "Carbon Neutrality in 2050," from R&D and demonstration to social implementation by FY2030. The program covers 14 fields: transportation/manufacturing-related industries including carbon recycling/materials industries, energy-related industries, and home/office-related industries.
*2. Biofoundry: Microorganism development platform that creates microorganisms with designed functions to efficiently produce useful substances
*3. Smart cell: A cell that is highly designed and has an enhanced ability to efficiently produce the desired substance
*4. Integrated Biofoundry: A one-stop biomanufacturing platform that provides everything from microbial breeding to process development
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005155/en/
Contact information
KANEKA CORPORATION
Investors & Public Relations Department
Chika Harada
Info_Pro@kaneka.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
